Citadel Advisors’s ProQR Therapeutics PRQR Stock Holding History

Citadel Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.14M	Buy	703,323 +120,101	+21%	+$197K	﹤0.01%	7364
2025 Q4	$1.18M	Sell	583,222 -73,790	-11%	-$172K	﹤0.01%	7036
2025 Q3	$1.4M	Buy	657,012 +277,749	+73%	+$607K	﹤0.01%	6808
2025 Q2	$774K	Sell	379,263 -439,595	-54%	-$715K	﹤0.01%	7643
2025 Q1	$1.09M	Buy	818,858 +410,051	+100%	+$873K	﹤0.01%	6771
2024 Q4	$1.08M	Buy	408,807 +321,830	+370%	+$1.02M	﹤0.01%	6845
2024 Q3	$158K	Buy	86,977 +68,612	+374%	+$129K	﹤0.01%	10494
2024 Q2	$30.5K	Sell	18,365 -27,643	-60%	-$53.7K	﹤0.01%	12255
2024 Q1	$104K	Sell	46,008 -31,808	-41%	-$68K	﹤0.01%	11303
2023 Q4	$154K	Buy	+77,816	New	+$120K	﹤0.01%	10342
2023 Q3	–	Sell	-116,792	Closed	-$189K	–	14923
2023 Q2	$189K	Buy	116,792 +17,013	+17%	+$33.2K	﹤0.01%	9984
2023 Q1	$213K	Buy	+99,779	New	+$305K	﹤0.01%	10081
2022 Q3	–	Sell	-209,215	Closed	-$168K	–	13382
2022 Q2	$162K	Buy	+209,215	New	+$156K	﹤0.01%	10906
2022 Q1	–	Sell	-222,269	Closed	-$745K	–	14365
2021 Q4	$1.78M	Buy	222,269 +130,063	+141%	+$990K	﹤0.01%	6513
2021 Q3	$772K	Buy	92,206 +34,076	+59%	+$223K	﹤0.01%	8807
2021 Q2	$392K	Buy	58,130 +29,754	+105%	+$192K	﹤0.01%	10617
2021 Q1	$188K	Buy	+28,376	New	+$145K	﹤0.01%	11780
2019 Q4	–	Sell	-65,996	Closed	-$380K	–	9605
2019 Q3	$380K	Buy	65,996 +22,971	+53%	+$183K	﹤0.01%	7212
2019 Q2	$391K	Sell	43,025 -39,314	-48%	-$464K	﹤0.01%	7181
2019 Q1	$1.14M	Buy	82,339 +30,367	+58%	+$454K	﹤0.01%	5365
2018 Q4	$819K	Buy	+51,972	New	+$954K	﹤0.01%	5599
2016 Q1	–	Sell	-11,960	Closed	-$103K	–	7712
2015 Q4	$103K	Sell	11,960 -1,676	-12%	-$19.3K	﹤0.01%	6643
2015 Q3	$198K	Buy	13,636 +634	+5%	+$10.6K	﹤0.01%	6173
2015 Q2	$217K	Buy	13,002 +3,405	+35%	+$64.1K	﹤0.01%	6213
2015 Q1	$210K	Buy	+9,597	New	+$198K	﹤0.01%	6121
2014 Q4	–	Sell	-108,715	Closed	-$1.87M	–	8679
2014 Q3	$1.87M	Buy	+108,715	New	+$1.74M	﹤0.01%	2915

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Citadel Advisors's PRQR Position: Q1 2026 in Review

Citadel Advisors increased its ProQR Therapeutics (PRQR) stake by 21% in Q1 2026, buying an estimated $197K and bringing the position to 703,323 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #7364.

Citadel Advisors first reported a position in PRQR in Q3 2014 and has held it in 26 quarters since. The position peaked at $1.87M in Q3 2014. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Citadel Advisors held 703,323 shares of ProQR Therapeutics worth $1.14M as of Q1 2026.
Citadel Advisors bought 120,101 ProQR Therapeutics shares in Q1 2026, an estimated $197K.
ProQR Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #7364 holding.
Citadel Advisors first reported a position in ProQR Therapeutics in Q3 2014 and has held it in 26 quarters since.
Citadel Advisors's ProQR Therapeutics position peaked at $1.87M in Q3 2014.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.